Jeff Z Chen1,2,3, Hisashi Sawada1,2,3, Dien Ye1,2, Yuriko Katsumata4,5, Masayoshi Kukida1,2, Satoko Ohno-Urabe1,2, Jessica J Moorleghen1,2, Michael K Franklin1,2, Deborah A Howatt1,2, Mary B Sheppard1,2,3,6,7, Adam E Mullick8, Hong S Lu1,2,3, Alan Daugherty1,2,3. 1. Saha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington. 2. Saha Aortic Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington. 3. Department of Physiology (J.Z.C., H.S., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington. 4. Department of Biostatistics (Y.K.), University of Kentucky, Lexington. 5. Sanders-Brown Center on Aging (Y.K.), University of Kentucky, Lexington. 6. Department of Family and Community Medicine (M.B.S.), University of Kentucky, Lexington. 7. Department of Surgery (M.B.S.), University of Kentucky, Lexington. 8. Ionis Pharmaceuticals, Carlsbad, CA (A.E.M.).
Abstract
Objective: A cardinal feature of Marfan syndrome is thoracic aortic aneurysm. The contribution of the renin-angiotensin system via AT1aR (Ang II [angiotensin II] receptor type 1a) to thoracic aortic aneurysm progression remains controversial because the beneficial effects of angiotensin receptor blockers have been ascribed to off-target effects. This study used genetic and pharmacological modes of attenuating angiotensin receptor and ligand, respectively, to determine their roles on thoracic aortic aneurysm in mice with fibrillin-1 haploinsufficiency (Fbn1C1041G/+). Approach and Results: Thoracic aortic aneurysm in Fbn1C1041G/+ mice was found to be strikingly sexual dimorphic. Males displayed aortic dilation over 12 months while aortic dilation in Fbn1C1041G/+ females did not differ significantly from wild-type mice. To determine the role of AT1aR, Fbn1C1041G/+ mice that were either +/+ or -/- for AT1aR were generated. AT1aR deletion reduced expansion of ascending aorta and aortic root diameter from 1 to 12 months of age in males. Medial thickening and elastin fragmentation were attenuated. An antisense oligonucleotide against angiotensinogen was administered to male Fbn1C1041G/+ mice to determine the effects of Ang II depletion. Antisense oligonucleotide against angiotensinogen administration attenuated dilation of the ascending aorta and aortic root and reduced extracellular remodeling. Aortic transcriptome analyses identified potential targets by which inhibition of the renin-angiotensin system reduced aortic dilation in Fbn1C1041G/+ mice. Conclusions: Deletion of AT1aR or inhibition of Ang II production exerted similar effects in attenuating pathologies in the proximal thoracic aorta of male Fbn1C1041G/+ mice. Inhibition of the renin-angiotensin system attenuated dysregulation of genes within the aorta related to pathology of Fbn1C1041G/+ mice.
Objective: A cardinal feature of Marfan syndrome is thoracic aortic aneurysm. The contribution of the renin-angiotensin system via AT1aR (Ang II [angiotensin II] receptor type 1a) to thoracic aortic aneurysm progression remains controversial because the beneficial effects of angiotensin receptor blockers have been ascribed to off-target effects. This study used genetic and pharmacological modes of attenuating angiotensin receptor and ligand, respectively, to determine their roles on thoracic aortic aneurysm in mice with fibrillin-1 haploinsufficiency (Fbn1C1041G/+). Approach and Results: Thoracic aortic aneurysm in Fbn1C1041G/+ mice was found to be strikingly sexual dimorphic. Males displayed aortic dilation over 12 months while aortic dilation in Fbn1C1041G/+ females did not differ significantly from wild-type mice. To determine the role of AT1aR, Fbn1C1041G/+ mice that were either +/+ or -/- for AT1aR were generated. AT1aR deletion reduced expansion of ascending aorta and aortic root diameter from 1 to 12 months of age in males. Medial thickening and elastin fragmentation were attenuated. An antisense oligonucleotide against angiotensinogen was administered to male Fbn1C1041G/+ mice to determine the effects of Ang II depletion. Antisense oligonucleotide against angiotensinogen administration attenuated dilation of the ascending aorta and aortic root and reduced extracellular remodeling. Aortic transcriptome analyses identified potential targets by which inhibition of the renin-angiotensin system reduced aortic dilation in Fbn1C1041G/+ mice. Conclusions: Deletion of AT1aR or inhibition of Ang II production exerted similar effects in attenuating pathologies in the proximal thoracic aorta of male Fbn1C1041G/+ mice. Inhibition of the renin-angiotensin system attenuated dysregulation of genes within the aorta related to pathology of Fbn1C1041G/+ mice.
Entities:
Keywords:
Marfan syndrome; angiotensin II; angiotensinogen; aortic aneurysm; renin-angiotensin system
Authors: Ami B Bhatt; J Stewart Buck; Jonah P Zuflacht; Jessica Milian; Samoneh Kadivar; Kimberlee Gauvreau; Michael N Singh; Mark A Creager Journal: Vasc Med Date: 2015-03-20 Impact factor: 3.239
Authors: Elena M Gallo; David C Loch; Jennifer P Habashi; Juan F Calderon; Yichun Chen; Djahida Bedja; Christel van Erp; Elizabeth E Gerber; Sarah J Parker; Kimberly Sauls; Daniel P Judge; Sara K Cooke; Mark E Lindsay; Rosanne Rouf; Loretha Myers; Colette M ap Rhys; Kathleen C Kent; Russell A Norris; David L Huso; Harry C Dietz Journal: J Clin Invest Date: 2013-12-20 Impact factor: 14.808
Authors: Frank S Cikach; Christopher D Koch; Timothy J Mead; Josephine Galatioto; Belinda B Willard; Kelly B Emerton; Matthew J Eagleton; Eugene H Blackstone; Francesco Ramirez; Eric E Roselli; Suneel S Apte Journal: JCI Insight Date: 2018-03-08
Authors: Daniel P Judge; Nancy J Biery; Douglas R Keene; Jessica Geubtner; Loretha Myers; David L Huso; Lynn Y Sakai; Harry C Dietz Journal: J Clin Invest Date: 2004-07 Impact factor: 14.808
Authors: Shao-Qing Kuang; Liang Geng; Siddharth K Prakash; Jiu-Mei Cao; Steven Guo; Carlos Villamizar; Callie S Kwartler; Andrew M Peters; Allan R Brasier; Dianna M Milewicz Journal: Arterioscler Thromb Vasc Biol Date: 2013-07-18 Impact factor: 8.311
Authors: Jennifer P Habashi; Jefferson J Doyle; Tammy M Holm; Hamza Aziz; Florian Schoenhoff; Djahida Bedja; YiChun Chen; Alexandra N Modiri; Daniel P Judge; Harry C Dietz Journal: Science Date: 2011-04-15 Impact factor: 47.728
Authors: Marjolijn Renard; Laura Muiño-Mosquera; Elise C Manalo; Sara Tufa; Eric J Carlson; Douglas R Keene; Julie De Backer; Lynn Y Sakai Journal: PLoS One Date: 2017-07-14 Impact factor: 3.240
Authors: Stijntje Hibender; Romy Franken; Cindy van Roomen; Anique Ter Braake; Ingeborg van der Made; Edith E Schermer; Quinn Gunst; Maurice J van den Hoff; Esther Lutgens; Yigal M Pinto; Maarten Groenink; Aeilko H Zwinderman; Barbara J M Mulder; Carlie J M de Vries; Vivian de Waard Journal: Arterioscler Thromb Vasc Biol Date: 2016-06-09 Impact factor: 8.311
Authors: Albert J Pedroza; Alex R Dalal; Rohan Shad; Nobu Yokoyama; Ken Nakamura; Paul Cheng; Robert C Wirka; Olivia Mitchel; Michael Baiocchi; William Hiesinger; Thomas Quertermous; Michael P Fischbein Journal: Arterioscler Thromb Vasc Biol Date: 2022-07-07 Impact factor: 10.514
Authors: Hisashi Sawada; Satoko Ohno-Urabe; Dien Ye; Michael K Franklin; Jessica J Moorleghen; Deborah A Howatt; Adam E Mullick; Alan Daugherty; Hong S Lu Journal: Arterioscler Thromb Vasc Biol Date: 2022-08-25 Impact factor: 10.514
Authors: Emily E Bramel; Rustam Bagirzadeh; Muzna Saqib; Tyler J Creamer; Wendy A Espinoza Camejo; LaToya Ann Roker; Jennifer Pardo Habashi; Harry C Dietz; Elena Gallo MacFarlane Journal: Front Cardiovasc Med Date: 2022-06-22